4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6

被引：76

作者：

Cho, Young Shin ^{[1
]}

Borland, Maria ^{[1
]}

Brain, Christopher ^{[1
]}

Chen, Christine H. -T ^{[1
]}

Cheng, Hong ^{[1
]}

Chopra, Rajiv ^{[1
]}

Chung, Kristy ^{[1
]}

Groarke, James ^{[1
]}

He, Guo ^{[1
]}

Hou, Ying ^{[1
]}

Kim, Sunkyu ^{[1
]}

Kovats, Steven ^{[1
]}

Lu, Yipin ^{[1
]}

O'Reilly, Marc ^{[2
]}

Shen, Junqing ^{[1
]}

Smith, Troy ^{[1
]}

Trakshel, Gary ^{[1
]}

Voegtle, Markus ^{[1
]}

Xu, Mei ^{[1
]}

Xu, Ming ^{[1
]}

Sung, Moo Je ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Cambridge, MA 02139 USA

[2] Astex Therapeut, Cambridge CB4 0QA, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2010年 / 53卷 / 22期

关键词：

CRYSTAL-STRUCTURE; D DYSREGULATION; CELL-CYCLE; PROTEIN; POTENT; CDK4; DESIGN; CANCER; AMPLIFICATION; EXPRESSION;

D O I：

10.1021/jm100571n

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Identification and structure-guided optimization of a series of 4-(pyrazol-4-yl)-pyrimidines as selective CDK 4/6 inhibitors is reported herein. Several potency and selectivity determinants were established based on the X-ray crystallographic analysis of representative compounds bound to monomeric CDK 6. Significant selectivity for CDK4/6 over CDK 1 and CDK2 was demonstrated with several compounds in both enzymatic and cellular assays.

引用

收藏

页码：7938 / 7957

页数：20

相关论文

共 73 条

[21] Crystal structure of human CDK4 in complex with a D-type cyclin [J].

Day, Philip J. ;

Cleasby, Anne ;

Tickle, Ian J. ;

O'Reilly, Marc ;

Coyle, Joe E. ;

Holding, Finn P. ;

McMenamin, Rachel L. ;

Yon, Jeff ;

Chopra, Rajiv ;

Lengauer, Christoph ;

Jhoti, Harren .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (11) :4166-4170

[22] Cyclins and cdks in development and cancer: a perspective [J].

Deshpande, A ;

Sicinski, P ;

Hinds, PW .

ONCOGENE, 2005, 24 (17) :2909-2915

[23] Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma [J].

Ely, S ;

Di Liberto, M ;

Niesvizky, R ;

Baughn, LB ;

Cho, HJ ;

Hatada, EN ;

Knowles, DM ;

Lane, J ;

Chen-Kiang, S .

CANCER RESEARCH, 2005, 65 (24) :11345-11353

[24]

Fry DW, 2004, MOL CANCER THER, V3, P1427

[25]

FU W, 2008, Patent No. 2008150899

[26] Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways [J].

Garcia-Echeverria, Carlos .

PURINERGIC SIGNALLING, 2009, 5 (01) :117-125

[27]

GARCIAECHEVERRIA C, 2005, Patent No. 2005068452

[28] ADDITION AND SUBSTITUTION-REACTIONS OF CHLOROPYRIMIDINES WITH LITHIUM REAGENTS [J].

HARDEN, DB ;

MOKROSZ, MJ ;

STREKOWSKI, L .

JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (17) :4137-4140

[29] Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases [J].

Hirai, H ;

Kawanishi, N ;

Iwasawa, Y .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) :167-179

[30] A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues [J].

Honma, T ;

Yoshizumi, T ;

Hashimoto, N ;

Hayashi, K ;

Kawanishi, N ;

Fukasawa, K ;

Takaki, T ;

Ikeura, C ;

Ikuta, M ;

Suzuki-Takahashi, I ;

Hayama, T ;

Nishimura, S ;

Morishima, H .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (26) :4628-4640

← 1 2 3 4 5 6 7 8 →